Although MORC3 protein is known to be involved in cellular senescence, p53 recruitment [40] and oncogenesis [41], the clear demonstration of the oncogenic potential of anti-NXP2 antibodies was not reported, so far, in contrast to what has been described for anti-TIF1gamma [42] or anti-RNAPol-III antibodies, specific for SSc [43]. The gene discussed is MORC3; the disease is systemic sclerosis.